• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DCRI, Pfizer, Premier partner on vaccination rates

DCRI, Pfizer, Premier partner on vaccination rates

August 30, 2016
CenterWatch Staff

A new quality improvement initiative that aims to create effective solutions in optimizing adult vaccination rates has been announced. The program, the Adult Immunization Project, is a collaboration among the Duke Clinical Research Institute (DCRI), Duke Primary Care, Pfizer and Premier. Researchers will jointly work to develop evidence-based interventions to support indicated adult vaccination practices among providers in the Duke Health system.

Improving adult vaccination rates has been a longstanding goal of the nation’s public health experts. Adults are more likely than children to contract vaccine-preventable diseases, largely because adult immunization rates are considerably lower than childhood rates. Real-world data show that pneumococcal, influenza, tetanus, and herpes zoster vaccination rates lag well behind national goals, particularly for high-risk patient populations. Nearly 50,000 American adults die each year from vaccine-preventable diseases or their complications.

“We all believe that adult immunization rates could be improved,” said Tracy Wang, M.D., MHS, MSc, faculty director for DCRI Education. “Less than half of all eligible adults in the U.S. get an annual flu vaccination, which is one of the more common vaccines. The rates of vaccinations for other diseases, such as shingles and pneumonia, are even lower.”

As part of the collaborative project, researchers at Duke will analyze data from primary care practices before, during and after the deployment of educational interventions to determine which approaches were successful in helping patients understand the benefits and risks associated with various vaccinations. The project will be piloted throughout Duke Primary Care practices, engaging frontline clinic staff on improving patient awareness and delivery of indicated and customary immunization care for current adult patients.

“With the data being collected, we’ll be able to better understand what motivates provider and patient behavior, and understand what types of interventions have the most traction,” said John Anderson, M.D., chief medical officer for Duke Primary Care.

Patient data will be stored, streamlined, and analyzed using Premier’s CECity quality analytics platform. The platform is a clinical data warehouse that allows healthcare providers to access patient information in a single, consolidated view. In addition to access of patient vaccination status, the platform allows providers to manage outlier reports, identify high-risk patients, and connect patients to appropriately targeted interventions. 

“Together, we are in a unique position to provide research-level analytics around an evidence-based quality improvement approach designed to help hospitals and health systems meet population health goals and implement effective, scalable prevention strategies,” said Leigh Anderson, senior vice president and chief information officer at Premier. 

The initiative is funded by Pfizer, which markets FDA-approved vaccine products in the U.S and has a number of vaccine candidates being evaluated in clinical trials.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing